Indeed, in ipilimumab-treated metastatic prostate cancer patients, almost 50% of circulating FoxP3+ Tregs expressed the proliferation marker Ki67 indicating they were proliferating efficiently in vivo [66]. Here, FOXP3 is linked to metastatic prostate carcinoma.